Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL and Other Hematologic Malignancies

October 15th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

A Real-World Case of a Patient with CLL and a Cardiac History

October 15th 2021

Farrukh Awan shares a case of a patient with a cardiac history recently diagnosed with CLL requiring treatment.

Strategies for Managing Atrial Fibrillation in Patients on BTKi

October 15th 2021

Two experts discuss strategies for managing atrial fibrillation in patients with CLL on BTKi therapy.

Dr. Danilov on the Rationale to Combine Entospletinib With Obinutuzumab in CLL

October 14th 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to combine entospletinib with obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Entospletinib Plus Obinutuzumab Shows Early Efficacy, Tolerability in High-Risk Relapsed/Refractory CLL

October 13th 2021

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Balancing the Risk and Benefit of Anticoagulation in Patients on BTKi

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review the risk versus benefit of anticoagulation strategies in patients on BTKi.

Baseline Testing Prior to Initiation of BTKi Treatment in CLL

October 7th 2021

Drs Lenneman and Awan discuss baseline testing before choosing a treatment strategy for battling chronic lymphocytic leukemia.

Key Safety Considerations

October 7th 2021

Two experts discuss key safety considerations when treating patients with chronic lymphocytic leukemia.

A Review of Treatment Options in CLL

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.

Frontline Ibrutinib Shows Sustained Survival Advantage Over Chlorambucil in CLL at 7 Years

October 6th 2021

Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.

Frontline Acalabrutinib Plus Venetoclax/Obinutuzumab Shows Promising Activity in CLL

September 29th 2021

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL

September 22nd 2021

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Thompson on the Results of the BRUIN Study in Patients With Richter's Transformation

September 21st 2021

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Robak on the Results of the 7-Year Follow-Up of RESONATE-2 in CLL

September 21st 2021

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. John Byrd Presented the Binet-Rai Medal Award at XIX International Workshop on Chronic Lymphocytic Leukemia

September 21st 2021

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation

September 20th 2021

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLL

September 20th 2021

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Results of a First-in-Human Study of Lisaftoclax in Hematologic Malignancies

September 20th 2021

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

PAK1 Emerges as a Potential Target in Ibrutinib-Resistant CLL

September 20th 2021

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.